Merck Gross Profit 2006-2019 | MRK

Merck annual/quarterly gross profit history and growth rate from 2006 to 2019. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Merck gross profit for the quarter ending June 30, 2019 was $8.359B, a 18.6% increase year-over-year.
  • Merck gross profit for the twelve months ending June 30, 2019 was $31.007B, a 11.09% increase year-over-year.
  • Merck annual gross profit for 2018 was $28.785B, a 5.79% increase from 2017.
  • Merck annual gross profit for 2017 was $27.21B, a 5.56% increase from 2016.
  • Merck annual gross profit for 2016 was $25.777B, a 4.94% increase from 2015.
Merck Annual Gross Profit
(Millions of US $)
2018 $28,785
2017 $27,210
2016 $25,777
2015 $24,564
2014 $25,469
2013 $27,079
2012 $30,821
2011 $31,176
2010 $27,591
2009 $18,409
2008 $18,267
2007 $18,057
2006 $16,635
2005 $16,862
Merck Quarterly Gross Profit
(Millions of US $)
Q2 2019 $8,359
Q1 2019 $7,764
Q4 2018 $7,709
Q3 2018 $7,175
Q2 2018 $7,048
Q1 2018 $6,853
Q4 2017 $6,993
Q3 2017 $7,018
Q2 2017 $6,814
Q1 2017 $6,385
Q4 2016 $6,644
Q3 2016 $7,127
Q2 2016 $6,266
Q1 2016 $5,740
Q4 2015 $6,365
Q3 2015 $6,312
Q2 2015 $6,031
Q1 2015 $5,856
Q4 2014 $6,733
Q3 2014 $6,334
Q2 2014 $6,041
Q1 2014 $6,361
Q4 2013 $6,713
Q3 2013 $6,928
Q2 2013 $6,726
Q1 2013 $6,712
Q4 2012 $7,577
Q3 2012 $7,351
Q2 2012 $8,199
Q1 2012 $7,694
Q4 2011 $8,118
Q3 2011 $7,670
Q2 2011 $7,867
Q1 2011 $7,521
Q4 2010 $7,654
Q3 2010 $6,934
Q2 2010 $6,797
Q1 2010 $6,206
Q4 2009 $5,192
Q3 2009 $4,619
Q2 2009 $4,546
Q1 2009 $4,051
Q4 2008 $4,562
Q3 2008 $4,466
Q2 2008 $4,655
Q1 2008 $4,584
Q4 2007 $4,698
Q3 2007 $4,556
Q2 2007 $4,559
Q1 2007 $4,244
Q4 2006 $4,375
Q3 2006 $3,866
Q2 2006 $4,327
Q1 2006 $4,067
Q4 2005 $4,287
Q3 2005 $4,177
Q2 2005 $4,307
Q1 2005 $4,091
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $217.785B $42.294B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $346.681B 15.10
Roche Holding AG (RHHBY) Switzerland $237.118B 0.00
Novartis AG (NVS) Switzerland $205.270B 17.65
Pfizer (PFE) United States $191.651B 11.29
Novo Nordisk (NVO) Denmark $126.560B 21.00
AstraZeneca (AZN) United Kingdom $112.309B 22.51
Eli Lilly (LLY) United States $106.700B 19.91
Sanofi (SNY) France $104.896B 12.93
GlaxoSmithKline (GSK) United Kingdom $99.695B 12.60
AbbVie (ABBV) United States $95.259B 7.63
Bristol-Myers Squibb (BMY) United States $76.848B 10.90
Bayer (BAYRY) Germany $66.954B 9.76
H Lundbeck (HLUYY) Denmark $8.015B 11.57